Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
27.07
+1.13 (4.36%)
Mar 24, 2026, 11:31 AM EDT - Market open
Centessa Pharmaceuticals Revenue
Centessa Pharmaceuticals had revenue of $15.00M in the twelve months ending September 30, 2025, up 118.88% year-over-year.
Revenue (ttm)
$15.00M
Revenue Growth
+118.88%
P/S Ratio
232.51
Revenue / Employee
$131,579
Employees
114
Market Cap
3.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 6.85M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Legend Biotech | 1.03B |
| Corcept Therapeutics | 761.41M |
| ADMA Biologics | 510.17M |
| Ligand Pharmaceuticals | 268.09M |
| NewAmsterdam Pharma Company | 22.50M |
| Crinetics Pharmaceuticals | 7.70M |
| Dianthus Therapeutics | 2.04M |
CNTA News
- 19 days ago - Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals - GlobeNewsWire
- 5 weeks ago - Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals - GlobeNewsWire
- 7 weeks ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting - GlobeNewsWire
- 2 months ago - Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications - GlobeNewsWire
- 4 months ago - Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 4 months ago - Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares - GlobeNewsWire